BioXcel Therapeutics (DB:BX2) - Hisse Senedi Fiyatı, Haberler ve Analizler

BX2 Stoklara Genel Bakış

BX2 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Gelirin yılda 64.06% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Negatif hissedar öz sermayesi

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

+ 2 daha fazla risk

BioXcel Therapeutics, Inc. Rakipler

2invest

XTRA:2INV

€63.2m

Medigene

XTRA:MDG1

€20.6m

co.don

XTRA:CNW

€6.5m

Heidelberg Pharma

XTRA:HPHA

€106.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti BioXcel Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.45
52 Haftanın En Yüksek Seviyesi	US$3.76
52 Haftanın En Düşük Seviyesi	US$0.43
Beta	0.29
11 Aylık Değişim	-17.70%
3 Aylık Değişim	-21.81%
1 Yıllık Değişim	-86.91%
33 Yıllık Değişim	-97.57%
5 Yıllık Değişim	-91.81%
Halka arzdan bu yana değişim	-94.37%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	BX2	DE Biotechs	DE Pazar
7D	-12.4%	-0.2%	0.8%
1Y	-86.9%	-16.9%	9.1%

Getiri vs. Endüstri: BX2 geçen yıl % -16.9 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: BX2 geçen yıl % 9.1 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is BX2's price volatile compared to industry and market?
BX2 volatility
BX2 Average Weekly Movement	14.3%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: BX2 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: BX2 'nin haftalık oynaklığı ( 14% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2017	74	Vimal Mehta	www.bioxceltherapeutics.com

Ticari aşamada bir biyofarmasötik şirketi olan BioXcel Therapeutics, Inc. nörobilim ve immüno-onkoloji alanlarında dönüştürücü ilaçlar geliştirmek için yapay zekâ yaklaşımlarından yararlanmaktadır. Şirketin ilaç yeniden inovasyon yaklaşımı, yeni terapötik endeksleri belirlemek için mevcut onaylı ilaçları ve/veya klinik olarak doğrulanmış ürün adaylarını büyük veri ve tescilli makine öğrenimi algoritmalarıyla birlikte kullanır. Ticari ürünü IGALMI, yetişkinlerde şizofreni veya bipolar I veya II bozukluk ile ilişkili ajitasyonun akut tedavisi için deksmedetomidinin dil altı film formülasyonudur.

BioXcel Therapeutics, Inc. Temel Bilgiler Özeti

BioXcel Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BX2 temel i̇stati̇sti̇kler
Piyasa değeri	€19.18m
Kazançlar(TTM)	-€67.77m
Gelir(TTM)	€2.17m

8.7x

P/S Oranı

-0.3x

F/K Oranı

BX2 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BX2 gelir tablosu (TTM)
Gelir	US$2.28m
Gelir Maliyeti	US$2.03m
Brüt Kâr	US$251.00k
Diğer Giderler	US$71.25m
Kazançlar	-US$71.00m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.66
Brüt Marj	11.03%
Net Kâr Marjı	-3,119.33%
Borç/Özkaynak Oranı	-122.0%

BX2 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BX2 Stoklara Genel Bakış

Ödüller

Risk Analizi

BioXcel Therapeutics, Inc. Rakipler

XTRA:2INV

€63.2m

XTRA:MDG1

€20.6m

XTRA:CNW

€6.5m

XTRA:HPHA

€106.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering.

Bioxcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia

BioXcel Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024

BioXcel Therapeutics, Inc. and University of North Carolina at Chapel Hill Announce U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

BioXcel Therapeutics Receives Non-Compliance Letters from Nasdaq Regarding Minimum Bid Price Requirement

BioXcel Therapeutics Receives Non-Compliance Letters from Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering.

Bioxcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia

BioXcel Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024

BioXcel Therapeutics, Inc. and University of North Carolina at Chapel Hill Announce U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

BioXcel Therapeutics Receives Non-Compliance Letters from Nasdaq Regarding Minimum Bid Price Requirement

BioXcel Therapeutics Receives Non-Compliance Letters from Nasdaq Regarding Minimum Bid Price Requirement

BioXcel Therapeutics, Inc. Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

BioXcel Therapeutics, Inc. Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Second quarter 2024 earnings released: US$0.21 loss per share (vs US$1.83 loss in 2Q 2023)

BioXcel Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) dropped from Russell 3000 Index

Bioxcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating Prn Treatment of Igalmi™ (Dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

First quarter 2024 earnings released: US$0.87 loss per share (vs US$1.85 loss in 1Q 2023)

BioXcel Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

BioXcel Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

Full year 2023 earnings released: US$6.15 loss per share (vs US$5.92 loss in FY 2022)

New major risk - Revenue and earnings growth

BioXcel Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

BioXcel Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $60 million.

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

BioXcel Therapeutics, Inc. Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of Bxcl701 in Combination with Keytruda®

BioXcel Therapeutics, Inc. Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine

New minor risk - Market cap size

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

BioXcel Therapeutics, Inc. Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

BioXcel Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Bioxcel Therapeutics, Inc. Receives Permanent J-Code for Igalmi (Dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

BioXcel Therapeutics, Inc. Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (Dexmedetomidine) Sublingual Film

BioXcel Therapeutics, Inc. Announces Board Changes

Bioxcel Therapeutics, Inc. Receives Notice of Allowance from the U.S. Patent and Trademark Office

Rain Oncology Inc., Proterra Inc., Bioxcel Therapeutics, Inc Announces Class Action Update

Jakubowitz Law Reminds BioXcel Shareholders of a Lead Plaintiff Deadline of September 5, 2023

BioXcel Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Bioxcel Therapeutics, Inc

BioXcel Therapeutics Announces Positive Topline Results from TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation

BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) dropped from Russell Small Cap Comp Value Index

Bioxcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal Security Iii Trial of Bxcl501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia

BioXcel Therapeutics, Inc., Annual General Meeting, Jun 26, 2023

BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MAD) Program

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2025

Insufficient new directors

Bioxcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 Asco Genitourinary Cancers Symposium

BioXcel Therapeutics, Inc. Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

Insufficient new directors

BioXcel Therapeutics, Inc. Announces First Patients Dosed in Serenity III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia

Insufficient new directors

BioXcel Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

BioXcel Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

BioXcel Therapeutics, Inc. Receives Two Notices of Allowance from the U.S. Patent and Trademark Office

BioXcel Therapeutics, Inc. Announces That Its Product, Igalmi™ (Dexmedetomidine), A Sublingual Film for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults, Is Now Available in Doses of 120 and 180 Mcg